Abstract: The present invention relates to methods of treatment useful in chronic diseases, by means of the rupture of tolerance to self-antigens and increasing autoimmune response against these antigens. More particularly, the present invention relates to methods useful in the treatment of tumors that are growth dependent on the Epidermal Growth Factor, including non-small cell lung carcinoma. In the present invention a therapeutic combination is revealed that includes the combination of a vaccine against self antigens with a monoclonal antibody against peripheral T cells or a chemotherapeutic drug able to induce a depletion of peripheral T cells.

Abstract: The present invention relates to the biotechnology and particularly with new products for use in human health. The present invention provides new specific monoclonal antibodies, which bind with high affinity sulfatides and sulfated proteoglycans. The anti sulfatides and anti sulfated proteoglycans antibodies disclosed in the present invention and described in the description, provide important diagnostic and therapeutic tools to act on pathological processes associated with the appearance of atherosclerotic plaques. Accordingly, the invention provides pharmaceutical compositions comprising MAbs of the invention or fragments thereof for the therapeutic and diagnostic use associated with cardiovascular diseases. Particularly, the present invention relates to the fragments derived from the MAbs that recognize sulfatides and sulfated proteoglycans, which can be used in the therapy or diagnosis of this pathology.

Abstract: The current invention relates to the field of Biotechnology applied to human health. Here it is described a vaccine vehicle wherein toxins from eukaryotic organisms are encapsulated into multilamellar vesicles obtained by the dehydration-rehydration procedure whose lipidic composition is dipalmitoylphosphatidylcholine:cholesterol in a 1:1 molar ratio for subcutaneous or intramuscular administration. These compositions do not require the use of other adjuvants. The disclosed compositions allow modulation of CTL-specific immune response against one or several antigens co-encapsulated into toxin-containing liposomes. The vaccinal vehicle of the present invention shows advantages over others disclosed by the previous art due to the robustness and functionality of the induced immune response as well as its immunomodulating properties.

Abstract: The present invention relates generally to polypeptides whose primary sequence has high sequence homology with human interleukin 2 (IL-2) with some punctual mutations in the sequence of native IL-2. The polypeptides of the present invention have an immunomodulatory effect on the immune system, which is selective/preferential on regulatory T cells. The present invention also relates to specific polypeptides whose amino acid sequence is disclosed herein. In another aspect the present invention relates to pharmaceutical compositions comprising as active ingredient the polypeptides disclosed. Finally, the present invention relates to the therapeutic use of the polypeptides and pharmaceutical compositions disclosed due to their immune modulating effect on diseases such as cancer and chronic infectious diseases.

Abstract: The present invention relates to the biotechnology and particularly with new products for use in human health. The present invention provides new specific monoclonal antibodies, which bind with high affinity sulfatides and sulfated proteoglycans. The anti sulfatides and anti sulfated proteoglycans antibodies disclosed in the present invention and described in the description, provide important diagnostic and therapeutic tools to act on pathological processes associated with the appearance of atherosclerotic plaques. Accordingly, the invention provides pharmaceutical compositions comprising MAbs of the invention or fragments thereof for the therapeutic and diagnostic use associated with cardiovascular diseases. Particularly, the present invention relates to the fragments derived from the MAbs that recognize sulfatides and sulfated proteoglycans, which can be used in the therapy or diagnosis of this pathology.

Abstract: A method of recovering mammalian cell clones adapted to serum and protein-free media is disclosed. The procedure includes a two-stage adaptation process to grow in that condition. A critical protein concentration interval is disclosed in which cells must grow in order to gain the capacity to survive in serum and protein-free condition, once the cells have grown at the critical interval concentrations, subsequent decreases of the concentration will affect neither viability nor cellular doubling time. The critical protein concentration interval is cell line specific. Furthermore, mammalian cells clones are disclosed, which are stable in serum- and protein-free media for at least 40 generations; additionally, clones disclosed express a recombinant product. The cell clones disclosed produce the humanized anti-EGF-R antibody hR3, the humanized anti-CD6 antibody T1hT, the chimeric anti CD3 antibody T3Q, or fragments thereof.

Abstract: The present invention relates to the biotechnological field and particularly to the human health. More particularly, the present invention relates to a vaccine composition for therapeutic use in cancer patients. The vaccine composition of the present invention has as active principle a chemical conjugated between the human recombinant Epidermal Growth Factor (hrEGF) and the P64K recombinant protein. In another embodiment, the present invention relates to the conjugation procedure to obtain, a chemical conjugated under controlled and reproducible parameters. In a preferred embodiment, the present invention relates to the procedure for purifying the chemical conjugated with a higher purity of the therapeutical vaccine composition, and a surprisingly increased immunogenic activity, inducing a significant increase of the anti-EGF antibody titers in humans.

Abstract: The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK) and of ligands for those receptors. Immunotherapeutic combinations are described that cause the blockade of RTK receptors and/or their ligands, by means of a combination of passive and active immunotherapy. The referenced procedures can be applied to patients in different clinical stages with tumors of epithelial origin that over-express those receptors. The combination of active and passive immunotherapy can be simultaneous or sequential independent of whether the therapeutic procedure will be used in patients with advanced disease or as adjuvant therapy.

Abstract: The present invention is related to the field of immunology and more specifically to cancer immunotherapy, particularly with immunotherapeutic combinations and treatment methods to prevent tumor cell growth and/or to eliminate those cells. The methods described in the present invention are based on the blockade of receptors with protein kinase activity in tyrosine residues (Receptor Tyrosine Kinases, RTK) and of ligands for those receptors. Immunotherapeutic combinations are described that cause the blockade of RTK receptors and/or their ligands, by means of a combination of passive and active immunotherapy. The referenced procedures can be applied to patients in different clinical stages with tumors of epithelial origin that over-express those receptors. The combination of active and passive immunotherapy can be simultaneous or sequential independent of whether the therapeutic procedure will be used in patients with advanced disease or as adjuvant therapy.

Abstract: The present invention relates to a method of recovering mammalian cell clones adapted to serum and protein-free media, the procedure includes a two-stage adaptation process to grow in that condition. The present invention discloses a critical protein concentration interval in which cells must grow in order to gain the capacity to survive in serum and protein-free condition, once the cells have grown at the critical interval concentrations, subsequent decreases of the concentration will affect neither viability nor cellular doubling time. The critical protein concentration interval is cell line specific. Furthermore, in the present invention mammalian cells clones are disclosed, which are stable in serum- and protein-free media for at least 40 generations; additionally, clones disclosed in the present invention express a recombinant product.

Abstract: Monoclonal antibodies that recognize the CD6 antigen, pharmaceutical compositions that recognizes and that are able to achieve a clinical and histological effectivity in patients with different clinical types of Psoriasis.

Abstract: Humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The humanized and monoclonal antibodies may comprise variable regions of non-human origin and constant regions of human origin with amino acid substitutions with the variable regions and/or framework regions. Use of the antibodies for therapeutical and diagnostic purposes is also disclosed.

Abstract: An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-Id monoclonal antibody of the present invention is capable of inducing a predominant anti-idiotypic response in xenogeneic models. The anti-idiotypic monoclonal antibody also exerts a protective effect against malignant tumors in animals.

Abstract: The present invention is related with the field of immunology and human medicine, particularly with the generation and selection of a monoclonal antibody (Mab) that recognizes the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tumors. One of the objectives of this invention is to provide a Mab of the IgG1 type that has the characteristic of recognizing with high specificity N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence presents in malignant tissues of breast, melanomas and tumors of the liver, stomach, colon, rectum and kidneys. It also has the capacity of producing direct cytolysis of the tumoral cells bearing the N-glycolylated-galactose-glucose sialic acid olygosaccharide sequence, thus can be used for the diagnosis and treatment of certain neoplasic diseases.

Abstract: The invention provides novel uses for n-glycolylated gangliosides and N-acetylated gangliosides, or derivatives and/or oligosaccharides thereof The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gangliosides may be coupled to carriers and may be accompanied by adjuvants. The vaccine compositions can be used in the treatment of breast cancers, whereby the gangliosides are used to elicit an immune response to corresponding gangliosides on breast tumor cells.

Abstract: An anti-idiotypic monoclonal antibody that is specific against the N-glycolyl residues of gangliosides, particularly those expressed by cancer cells. The monoclonal antibody is useful as an immunomodulator for cancer treatment. Specifically, the anti-idiotype monoclonal antibody of the present invention is capable of inducing a predominant anti-idiotypic response in xenogeneic models. The anti-idiotypic monoclonal antibody also exerts a protective effect against malignant tumors in animals.

Abstract: New humanized and chimeric monoclonal antibodies that recognize EGF-R and comprise an artificial sequence at least of the FRs of the heavy chain variable region of a human immunoglobulin. The hypervariable regions of both monoclonal antibodies is the following amino acid sequence: light chain:CDR-1: arg-ser-ser-gln-asn-ile-val-his-ser-asn-gly-asn-thr-tyr-leu-asp;CDR-2: lys-val-ser-asn-arg-phe-ser;CDR-3: phe-gln-tyr-ser-hys-val-pro-trp-thr.Heavy chain:CDR-1: asn-tyr-tyr-ile-tyr;CDR-2: gly-ile-asn-pro-thr-ser-gly-gly-ser-asn-phe-asn-glu-lys-phe-lys-thr;CDR-3: gln-gly-leu-trp-phe-asp-ser-asp-gly-arg-gly-phe-asp-phe.Use of the antibodies for therapeutical and diagnostic purposes.

Abstract: The present invention relates to immunotherapy strategies for the treatment of malignancies. The present immunotherapy strategies have gangliosides as a target. Gangliosides are glycosphingolipids which are present on normal cells and on malignant cells. On malignant cells they are more abundant and expressed in a different organization and conformation. The present invention provides antibodies which recognize these gangliosides, which antibodies are specific, have recurrent idiotypes and have value as immunoregulators. The invention further provides anti-idiotypic antibodies against anti-ganglioside antibodies. These are useful in vaccination strategies.

Abstract: The invention provides novel uses for n-glycolylated gangliosides, or derivatives and/or oligosaccharides thereof. The invention further provides methods of obtaining such gangliosides, as well as vaccine compositions comprising said gangliosides. The gangliosides may be coupled to carriers and may be accompanied by adjuvants. The vaccine compositions can be used in the treatment of breast cancers, whereby the gangliosides are used to elicit an immune response to corresponding gangliosides on breast tumour cells.